{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:55:33Z","timestamp":1791489333461,"version":"4.3.4"},"reference-count":346,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2019,12,27]]},"DOI":"10.3233\/jad-190744","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T14:11:22Z","timestamp":1569593482000},"page":"S145-S176","source":"Crossref","is-referenced-by-count":33,"title":["Current and Emerging Pharmacological Targets for the Treatment of Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"72","author":[{"given":"Ahmed","family":"Morsy","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA"},{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Trippier","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA"},{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA"},{"name":"UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-190744_ref1","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010-2050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-190744_ref2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde\"","volume":"8","author":"Alzheimer","year":"1995","journal-title":"Clin Anat"},{"key":"10.3233\/JAD-190744_ref3","first-page":"271","article-title":"Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2","volume":"387","author":"Neve","year":"1986","journal-title":"Brain Res"},{"key":"10.3233\/JAD-190744_ref4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-190744_ref5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S0140-6736(11)60582-5","article-title":"The three stages of Alzheimer\u2019s disease","volume":"377","author":"The Lancet","year":"2011","journal-title":"Lancet"},{"key":"10.3233\/JAD-190744_ref6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13803390903540315","article-title":"Diagnosis of Alzheimer\u2019s disease using neuropsychological testing improved by multivariate analyses","volume":"32","author":"Chapman","year":"2010","journal-title":"J Clin Exp Neuropsychol"},{"key":"10.3233\/JAD-190744_ref7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jnc.13411","article-title":"The contribution of neuroinflammation to amyloid toxicity in Alzheimer\u2019s disease","volume":"136","author":"Minter","year":"2016","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-190744_ref8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S1474-4422(17)30376-9","article-title":"Alzheimer\u2019s disease: Evolution of research diagnostic criteria","volume":"16","author":"The","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-190744_ref9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-190744_ref10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-190744_ref11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-190744_ref12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2174\/1567205014666170203125942","article-title":"Biomarkers for Alzheimer\u2019s disease diagnosis","volume":"14","author":"Mantzavinos","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190744_ref13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1126\/science.3810169","article-title":"Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer\u2019s disease","volume":"235","author":"Goldgaber","year":"1987","journal-title":"Science"},{"key":"10.3233\/JAD-190744_ref14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"Kang","year":"1987","journal-title":"Nature"},{"key":"10.3233\/JAD-190744_ref15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/329156a0","article-title":"The genetic defect in familial Alzheimer\u2019s disease is not tightly linked to the amyloid beta-protein gene","volume":"329","author":"Tanzi","year":"1987","journal-title":"Nature"},{"key":"10.3233\/JAD-190744_ref16","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.3390\/ijms13067303","article-title":"The toxicity of amyloid beta oligomers","volume":"13","author":"Zhao","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-190744_ref17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The role of amyloid-beta oligomers in toxicity, propagation, and immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"EBioMedicine"},{"key":"10.3233\/JAD-190744_ref18","doi-asserted-by":"crossref","first-page":"a006338","DOI":"10.1101\/cshperspect.a006338","article-title":"Neurotoxicity of amyloid beta-protein: Synatic and network dysfunction","volume":"2","author":"Mucke","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.3233\/JAD-190744_ref19","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1074\/jbc.M808755200","article-title":"Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers","volume":"284","author":"Gralle","year":"2009","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","article-title":"An overview of APP processing enzymes and products","volume":"12","author":"Chow","year":"2010","journal-title":"Neuromolecular Med"},{"key":"10.3233\/JAD-190744_ref21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-6606-4-3","article-title":"APP processing in Alzheimer\u2019s disease","volume":"4","author":"Zhang","year":"2011","journal-title":"Mol Brain"},{"key":"10.3233\/JAD-190744_ref22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3233\/JAD-2010-101020","article-title":"Amyloid-beta as a modulator of synaptic plasticity","volume":"22","author":"Parihar","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/157015906776359531","article-title":"The role of beta-amyloid protein in synaptic function: Implications for Alzheimer\u2019s disease therapy","volume":"4","author":"Pena","year":"2006","journal-title":"Curr Neuropharmacol"},{"key":"10.3233\/JAD-190744_ref24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"key":"10.3233\/JAD-190744_ref25","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3390\/ijms15034671","article-title":"Tau protein modifications and interactions: Their role in function and dysfunction","volume":"15","author":"Mietelska-Porowska","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-190744_ref26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fnmol.2014.00065","article-title":"Physiological and pathological phosphorylation of tau by Cdk5","volume":"7","author":"Kimura","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JAD-190744_ref27","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer\u2019s disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-190744_ref28","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1212\/WNL.0000000000006075","article-title":"Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease","volume":"91","author":"Aschenbrenner","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-190744_ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1424"},{"key":"10.3233\/JAD-190744_ref30","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1021\/jm3015926","article-title":"Target- and mechanism-based therapeutics for neurodegenerative diseases: Strength in numbers","volume":"56","author":"Trippier","year":"2013","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-190744_ref31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"\u03b2-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"key":"10.3233\/JAD-190744_ref32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/34910","article-title":"Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein","volume":"391","author":"De Strooper","year":"1998","journal-title":"Nature"},{"key":"10.3233\/JAD-190744_ref33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1750-3639.2008.00132.x","article-title":"Abeta-degrading enzymes in Alzheimer\u2019s disease","volume":"18","author":"Miners","year":"2008","journal-title":"Brain Pathol"},{"key":"10.3233\/JAD-190744_ref34","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A beta oligomers - a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-190744_ref35","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1096\/fj.04-1764com","article-title":"Targeting the neurotoxic species in Alzheimer\u2019s disease: Inhibitors of Abeta oligomerization","volume":"18","author":"De Felice","year":"2004","journal-title":"FASEB J"},{"key":"10.3233\/JAD-190744_ref36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190744_ref37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.3233\/JAD-190744_ref38","first-page":"149","article-title":"Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer\u2019s disease suggest disease modification potential","volume":"4","author":"Abushakra","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer\u2019s disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.3233\/JAD-190744_ref40","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","article-title":"Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain","volume":"32","author":"Hey","year":"2018","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-190744_ref41","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1016\/j.bmcl.2014.05.008","article-title":"Naturally occurring polyphenolic inhibitors of amyloid beta aggregation","volume":"24","author":"Churches","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3233\/JAD-190744_ref42","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1021\/bi500910b","article-title":"Capping of Abeta42 oligomers by small molecule inhibitors","volume":"53","author":"Fu","year":"2014","journal-title":"Biochemistry"},{"key":"10.3233\/JAD-190744_ref43","doi-asserted-by":"crossref","first-page":"38992","DOI":"10.1074\/jbc.M112.348037","article-title":"A novel inhibitor of amyloid beta (Abeta) peptide aggregation: From high throughput screening to efficacy in an animal model of Alzheimer disease","volume":"287","author":"McKoy","year":"2012","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref44","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1074\/jbc.M110.173856","article-title":"Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways","volume":"286","author":"Ladiwala","year":"2011","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1471-4159.2011.07187.x","article-title":"Low-n oligomers as therapeutic targets of Alzheimer\u2019s disease","volume":"117","author":"Ono","year":"2011","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-190744_ref46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/nbm.927","article-title":"Scyllo-inositol in normal aging human brain: 1H magnetic resonance sectroscopy study at 4 Tesla","volume":"18","author":"Kaiser","year":"2005","journal-title":"NMR Biomed"},{"key":"10.3233\/JAD-190744_ref47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00109-007-0156-7","article-title":"Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology","volume":"85","author":"Fenili","year":"2007","journal-title":"J Mol Med (Berl)"},{"key":"10.3233\/JAD-190744_ref48","doi-asserted-by":"crossref","first-page":"18495","DOI":"10.1074\/jbc.M906994199","article-title":"Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Abeta -induced toxicity","volume":"275","author":"McLaurin","year":"2000","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm1423","article-title":"Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model","volume":"12","author":"McLaurin","year":"2006","journal-title":"Nat Med"},{"key":"10.3233\/JAD-190744_ref50","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-190744_ref51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.3233\/JAD-190744_ref52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"10.3233\/JAD-190744_ref53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nri1843","article-title":"Immunology and immunotherapy of Alzheimer\u2019s disease","volume":"6","author":"Weiner","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.3233\/JAD-190744_ref54","first-page":"1005","article-title":"Inflammation in Alzheimer disease: Driving force, bystander or beneficial response?","volume":"12","author":"Wyss-Coray","year":"2006","journal-title":"Nat Med"},{"key":"10.3233\/JAD-190744_ref55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bcp.2014.01.008","article-title":"Microglial dysfunction in brain aging and Alzheimer\u2019s disease","volume":"88","author":"Mosher","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-190744_ref56","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","article-title":"The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects","volume":"31","author":"Wiessner","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer\u2019s disease: A phase 2b study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-190744_ref58","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1523\/JNEUROSCI.5924-12.2013","article-title":"MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-Abeta antibody response and attenuates Abeta pathology and cognitive deficits in APPswe\/PS1DeltaE9 transgenic mice","volume":"33","author":"Liu","year":"2013","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref59","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: Prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref60","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-190744_ref61","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-190744_ref62","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","volume":"88","author":"Relkin","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-190744_ref63","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-To-moderate Alzheimer\u2019s disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-190744_ref65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":"Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JAD-190744_ref66","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-190744_ref67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer\u2019s disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-190744_ref68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-190744_ref70","first-page":"255","article-title":"Clinical development of aducanumab, an anti-Abeta human monoclonal antibody being investigated for the treatment of early Alzheimer\u2019s disease","volume":"4","author":"Budd Haeberlein","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref71","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.3233\/JAD-190744_ref72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-190744_ref73","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ana.25513","article-title":"Target engagement in an Alzheimer trial: Crenezumab lowers amyloid beta oligomers in cerebrospinal fluid","volume":"86","author":"Yang","year":"2019","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-190744_ref74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-190744_ref75","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1172\/JCI21746","article-title":"Amyloid at the cutting edge: Activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model","volume":"113","author":"Lichtenthaler","year":"2004","journal-title":"J Clin Invest"},{"key":"10.3233\/JAD-190744_ref76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: Enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-190744_ref77","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1096\/fj.08-121392","article-title":"Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin","volume":"23","author":"Tippmann","year":"2009","journal-title":"FASEB J"},{"key":"10.3233\/JAD-190744_ref78","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/emboj.2010.167","article-title":"ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons","volume":"29","author":"Kuhn","year":"2010","journal-title":"EMBO J"},{"key":"10.3233\/JAD-190744_ref79","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000334300","article-title":"Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein","volume":"10","author":"Holthoewer","year":"2012","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JAD-190744_ref80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2017.09.008","article-title":"Targeting demyelination via alpha-secretases promoting sAPPalpha release to enhance remyelination in central nervous system","volume":"109","author":"Llufriu-Daben","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-190744_ref81","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","article-title":"Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing","volume":"106","author":"Marcade","year":"2008","journal-title":"J\u00a0Neurochem"},{"key":"10.3233\/JAD-190744_ref82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1567205012666141218141904","article-title":"Acute oral bryostatin-1 administration improves learning deficits in the APP\/PS1 transgenic mouse model of Alzheimer\u2019s disease","volume":"12","author":"Schrott","year":"2015","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190744_ref83","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-180759","article-title":"A randomized, double-blind, placebo-controlled, phase II study assessing safety, tolerability, and efficacy of bryostatin in the treatment of moderately severe to severe Alzheimer\u2019s disease","volume":"67","author":"Farlow","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref84","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/alzrt82","article-title":"The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer\u2019s disease","volume":"3","author":"Vassar","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-190744_ref85","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","article-title":"The beta-secretase enzyme BACE in health and Alzheimer\u2019s disease: Regulation, cell biology, function, and therapeutic potential","volume":"29","author":"Vassar","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref86","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1021\/acs.jmedchem.6b00307","article-title":"Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-a beta-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer\u2019s disease","volume":"59","author":"Scott","year":"2016","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-190744_ref87","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer\u2019s disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-190744_ref88","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-190744_ref89","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-190744_ref90","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fncel.2014.00427","article-title":"The gamma-secretase complex: From structure to function","volume":"8","author":"Zhang","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JAD-190744_ref91","first-page":"943","article-title":"Gamma secretase inhibitors of Notch signaling","volume":"6","author":"Olsauskas-Kuprys","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.3233\/JAD-190744_ref92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/alzrt225","article-title":"Nanoparticulate flurbiprofen reduces amyloid-beta42 generation in an in vitro blood-brain barrier model","volume":"5","author":"Meister","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-190744_ref93","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1021\/bi400377p","article-title":"Development and mechanism of gamma-secretase modulators for Alzheimer\u2019s disease","volume":"52","author":"Crump","year":"2013","journal-title":"Biochemistry"},{"key":"10.3233\/JAD-190744_ref94","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2174\/0929867323666160405112353","article-title":"Selecting good \u2018drug-like\u2019 properties to optimize small molecule blood-brain barrier penetration","volume":"23","author":"Trippier","year":"2016","journal-title":"Curr Med Chem"},{"key":"10.3233\/JAD-190744_ref95","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1074\/jbc.M111.305227","article-title":"First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms","volume":"287","author":"Borgegard","year":"2012","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref96","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/medicines2030127","article-title":"Natural product and natural product-derived gamma secretase modulators from Actaea Racemosa extracts","volume":"2","author":"Findeis","year":"2015","journal-title":"Medicines (Basel)"},{"key":"10.3233\/JAD-190744_ref97","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000101832","article-title":"Curcumin derivatives inhibit or modulate beta-amyloid precursor protein metabolism","volume":"4","author":"Narlawar","year":"2007","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JAD-190744_ref98","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1582-4934.2008.00344.x","article-title":"Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer\u2019s disease beta-amyloid production","volume":"13","author":"Rezai-Zadeh","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.3233\/JAD-190744_ref99","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.trci.2016.09.003","article-title":"NGP 555, a gamma-secretase modulator, lowers the amyloid biomarker, Abeta42, in cerebrospinal fluid while preventing Alzheimer\u2019s disease cognitive decline in rodents","volume":"3","author":"Kounnas","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-190744_ref100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase inhibitors for the treatment of Alzheimer\u2019s disease: Long road ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-190744_ref101","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","article-title":"Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190744_ref102","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer\u2019s disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.3233\/JAD-190744_ref103","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1073\/pnas.1207022109","article-title":"Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer\u2019s disease","volume":"109","author":"Frieden","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190744_ref104","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer\u2019s disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190744_ref105","doi-asserted-by":"crossref","first-page":"17574","DOI":"10.1038\/s41598-018-35687-8","article-title":"A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer\u2019s disease mouse model","volume":"8","author":"Campagna","year":"2018","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-190744_ref106","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/nbdi.2002.0483","article-title":"Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer\u2019s disease","volume":"9","author":"Fagan","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-190744_ref107","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/156720507780362173","article-title":"Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: Relevance to Alzheimer\u2019s disease theraeutics","volume":"4","author":"Cao","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190744_ref108","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","article-title":"Apolipoprotein E as a therapeutic target in Alzheimer\u2019s disease: A review of basic research and clinical evidence","volume":"30","author":"Yamazaki","year":"2016","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-190744_ref109","doi-asserted-by":"crossref","first-page":"814.4","DOI":"10.1096\/fasebj.31.1_supplement.814.4","article-title":"ApoE remodeling as a therapeutic target for Alzheimer\u2019s disease","volume":"31","author":"Ladu","year":"2017","journal-title":"FASEB J"},{"key":"10.3233\/JAD-190744_ref110","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","article-title":"Clearance of Alzheimer\u2019s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier","volume":"106","author":"Shibata","year":"2000","journal-title":"J Clin Invest"},{"key":"10.3233\/JAD-190744_ref111","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuron.2004.07.017","article-title":"LRP\/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms","volume":"43","author":"Deane","year":"2004","journal-title":"Neuron"},{"key":"10.3233\/JAD-190744_ref112","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","article-title":"Clearance of amyloid-beta by circulating lipoprotein receptors","volume":"13","author":"Sagare","year":"2007","journal-title":"Nat Med"},{"key":"10.3233\/JAD-190744_ref113","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-190744_ref114","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrn2620","article-title":"Apolipoprotein E and its receptors in Alzheimer\u2019s disease: Pathways, pathogenesis and therapy","volume":"10","author":"Bu","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-190744_ref115","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1161\/01.STR.0000143452.85382.d1","article-title":"RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier","volume":"35","author":"Deane","year":"2004","journal-title":"Stroke"},{"key":"10.3233\/JAD-190744_ref116","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1523\/JNEUROSCI.2052-12.2013","article-title":"High-mobility group box-1 protein and beta-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products\/nuclear factor-kappaB axis: Relevance for Alzheimer\u2019s disease","volume":"33","author":"Meneghini","year":"2013","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref117","first-page":"149","article-title":"Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease","volume":"5","author":"Burstein","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref118","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1523\/JNEUROSCI.2984-08.2009","article-title":"Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice","volume":"29","author":"Meilandt","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref119","first-page":"383796","article-title":"The Alzheimer\u2019s amyloid-degrading peptidase, neprilysin: Can we control it?","volume":"2012","author":"Nalivaeva","year":"2012","journal-title":"Int J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tem.2015.11.003","article-title":"Targeting insulin-degrading enzyme to treat type 2 Diabetes Mellitus","volume":"27","author":"Tang","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.3233\/JAD-190744_ref121","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/acel.12074","article-title":"Reduced amyloid-beta degradation in early Alzheimer\u2019s disease but not in the APPswePS1dE9 and 3xTg-AD mouse models","volume":"12","author":"Stargardt","year":"2013","journal-title":"Aging Cell"},{"key":"10.3233\/JAD-190744_ref122","doi-asserted-by":"crossref","first-page":"e8764","DOI":"10.1371\/journal.pone.0008764","article-title":"Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer\u2019s disease","volume":"5","author":"Carrasquillo","year":"2010","journal-title":"PLoS One"},{"key":"10.3233\/JAD-190744_ref123","doi-asserted-by":"crossref","first-page":"E106","DOI":"10.1152\/ajpendo.00279.2018","article-title":"Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues","volume":"316","author":"Kulas","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.3233\/JAD-190744_ref124","doi-asserted-by":"crossref","first-page":"13275","DOI":"10.1021\/acsomega.8b01913","article-title":"Resveratrol sustains insulin-degrading enzyme activity toward Abeta42","volume":"3","author":"Krasinski","year":"2018","journal-title":"ACS Omega"},{"key":"10.3233\/JAD-190744_ref125","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JAD-160492","article-title":"Stimulating the activity of amyloid-beta degrading enzymes: A novel approach for the therapeutic manipulation of amyloid-beta levels","volume":"54","author":"Kuruppu","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref126","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2174\/156720508783954785","article-title":"Amyloid-degrading enzymes as therapeutic targets in Alzheimer\u2019s disease","volume":"5","author":"Nalivaeva","year":"2008","journal-title":"Curr Alzheimer Res"},{"issue":"Suppl 1","key":"10.3233\/JAD-190744_ref127","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1471-4159.2011.07510.x","article-title":"Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer\u2019s disease?","volume":"120","author":"Nalivaeva","year":"2012","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-190744_ref128","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-beta and tau: The trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-190744_ref129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-190744_ref130","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12031-011-9576-5","article-title":"Immunotherapy for tauopathies","volume":"45","author":"Gu","year":"2011","journal-title":"J Mol Neurosci"},{"key":"10.3233\/JAD-190744_ref131","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1523\/JNEUROSCI.3192-13.2014","article-title":"Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles","volume":"34","author":"Castillo-Carranza","year":"2014","journal-title":"J Neurosci"},{"issue":"Suppl 1","key":"10.3233\/JAD-190744_ref132","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.3233\/JAD-132477","article-title":"Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds","volume":"40","author":"Castillo-Carranza","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref133","first-page":"63","article-title":"AADvac1, an active immunotherapy for Alzheimer\u2019s disease and non Alzheimer tauopathies: An overview of preclinical and clinical development","volume":"6","author":"Novak","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref134","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.3233\/JAD-179937","article-title":"Tau immunotherapies for Alzheimer\u2019s disease and related tauopathies: Progress and potential pitfalls","volume":"64","author":"Sigurdsson","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejmech.2015.10.018","article-title":"Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer\u2019s disease","volume":"107","author":"Maqbool","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-190744_ref136","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref137","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.chembiol.2015.03.009","article-title":"Tamoxifen inhibits CDK5 kinase activity by interacting with p35\/p25 and modulates the pattern of tau phosphorylation","volume":"22","author":"Corbel","year":"2015","journal-title":"Chem Biol"},{"key":"10.3233\/JAD-190744_ref138","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1007\/s12035-015-9369-x","article-title":"The role of Cdk5 in Alzheimer\u2019s disease","volume":"53","author":"Liu","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-190744_ref139","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JAD-190744_ref140","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","article-title":"Features of selective kinase inhibitors","volume":"12","author":"Knight","year":"2005","journal-title":"Chem Biol"},{"key":"10.3233\/JAD-190744_ref141","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/ml500450c","article-title":"Inhibition of O-GlcNAcase (OGA): A potential therapeutic target to treat Alzheimer\u2019s disease","volume":"5","author":"Abdel-Magid","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.3233\/JAD-190744_ref142","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuropharm.2013.11.025","article-title":"Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy","volume":"79","author":"Graham","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-190744_ref143","doi-asserted-by":"crossref","first-page":"E1160","DOI":"10.3390\/ijms19041160","article-title":"An overview on the clinical development of tau-based therapeutics","volume":"19","author":"Medina","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-190744_ref144","doi-asserted-by":"crossref","first-page":"13888","DOI":"10.1073\/pnas.1009038107","article-title":"Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer\u2019s disease models","volume":"107","author":"van Eersel","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190744_ref145","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jocn.2010.04.020","article-title":"Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer\u2019s disease model","volume":"17","author":"Corcoran","year":"2010","journal-title":"J Clin Neurosci"},{"key":"10.3233\/JAD-190744_ref146","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-160544","article-title":"A phase IIa randomized control trial of VEL015 (Sodium Selenate) in mild-moderate Alzheimer\u2019s disease","volume":"54","author":"Malpas","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref147","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nbd.2005.03.020","article-title":"Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models","volume":"20","author":"Ferrer","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-190744_ref148","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jnc.13018","article-title":"A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer\u2019s disease: Effect on tau and amyloid pathologies in vitro","volume":"133","author":"Coutadeur","year":"2015","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-190744_ref149","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","article-title":"The role of DYRK1A in neurodegenerative diseases","volume":"278","author":"Wegiel","year":"2011","journal-title":"FEBS J"},{"key":"10.3233\/JAD-190744_ref150","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/acel.12648","article-title":"Dyrk1 inhibition improves Alzheimer\u2019s disease-like pathology","volume":"16","author":"Branca","year":"2017","journal-title":"Aging Cell"},{"key":"10.3233\/JAD-190744_ref151","doi-asserted-by":"crossref","first-page":"15418","DOI":"10.1074\/jbc.M112.448183","article-title":"Prostate-derived sterile 20-like kinases (PSKs\/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease","volume":"288","author":"Tavares","year":"2013","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref152","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40478-018-0539-8","article-title":"A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies","volume":"6","author":"Giacomini","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-190744_ref153","doi-asserted-by":"crossref","first-page":"12230","DOI":"10.1523\/JNEUROSCI.1694-14.2014","article-title":"Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid beta","volume":"34","author":"Ma","year":"2014","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref154","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1042\/BJ20101485","article-title":"AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure","volume":"434","author":"Thornton","year":"2011","journal-title":"Biochem J"},{"key":"10.3233\/JAD-190744_ref155","doi-asserted-by":"crossref","first-page":"26758","DOI":"10.1038\/srep26758","article-title":"AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo","volume":"6","author":"Domise","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-190744_ref156","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/jnen\/59.11.966","article-title":"Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: A fluorescence resonance energy transfer study","volume":"59","author":"Chin","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-190744_ref157","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1523\/JNEUROSCI.2824-07.2008","article-title":"The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy","volume":"28","author":"Mocanu","year":"2008","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref158","doi-asserted-by":"crossref","first-page":"31755","DOI":"10.1074\/jbc.M705282200","article-title":"The beta-propensity of tau determines aggregation and synaptic loss in inducible mouse models of tauopathy","volume":"282","author":"Eckermann","year":"2007","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref159","doi-asserted-by":"crossref","first-page":"e0124816","DOI":"10.1371\/journal.pone.0124816","article-title":"MARK\/Par1 kinase is activated downstream of NMDA receptors through a PKA-dependent mechanism","volume":"10","author":"Bernard","year":"2015","journal-title":"PLoS One"},{"key":"10.3233\/JAD-190744_ref160","doi-asserted-by":"crossref","first-page":"e1005917","DOI":"10.1371\/journal.pgen.1005917","article-title":"Stabilization of microtubule-unbound tau via tau phosphorylation at Ser262\/356 by Par-1\/MARK contributes to Augmentation of AD-related phosphorylation and Abeta42-induced tau toxicity","volume":"12","author":"Ando","year":"2016","journal-title":"PLoS Genet"},{"key":"10.3233\/JAD-190744_ref161","doi-asserted-by":"crossref","first-page":"10047","DOI":"10.1021\/bi901090m","article-title":"Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules","volume":"48","author":"Fischer","year":"2009","journal-title":"Biochemistry"},{"key":"10.3233\/JAD-190744_ref162","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1007\/s00018-017-2574-1","article-title":"Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer\u2019s disease","volume":"74","author":"Annadurai","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.3233\/JAD-190744_ref163","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","article-title":"Cholinergic system during the progression of Alzheimer\u2019s disease: Therapeutic implications","volume":"8","author":"Mufson","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.3233\/JAD-190744_ref164","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejmech.2016.10.060","article-title":"A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer\u2019s disease","volume":"128","author":"Sameem","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-190744_ref165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.3233\/JAD-190744_ref166","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: International randomised controlled trial","volume":"318","author":"R\u00f6sler","year":"1999","journal-title":"BMJ"},{"key":"10.3233\/JAD-190744_ref167","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JAD-190744_ref168","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.3233\/JAD-190744_ref169","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.3390\/ijms18081813","article-title":"Towards a better understanding of GABAergic remodeling in Alzheimer\u2019s disease","volume":"18","author":"Govindpani","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-190744_ref170","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1523\/JNEUROSCI.6162-08.2009","article-title":"Distinct roles of GABA(A) and GABA(B) receptors in balancing and terminating persistent cortical activity","volume":"29","author":"Mann","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref171","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev-neuro-071714-034002","article-title":"Plasticity of cortical excitatory-inhibitory balance","volume":"38","author":"Froemke","year":"2015","journal-title":"Annu Rev Neurosci"},{"key":"10.3233\/JAD-190744_ref172","doi-asserted-by":"crossref","first-page":"20150429","DOI":"10.1098\/rstb.2015.0429","article-title":"Impairments of neural circuit function in Alzheimer\u2019s disease","volume":"B 371","author":"Busche","year":"2016","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.3233\/JAD-190744_ref173","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1074\/jbc.M109.030023","article-title":"Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure","volume":"285","author":"Parodi","year":"2010","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref174","doi-asserted-by":"crossref","first-page":"e11820","DOI":"10.1371\/journal.pone.0011820","article-title":"Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property","volume":"5","author":"Sepulveda","year":"2010","journal-title":"PLoS One"},{"key":"10.3233\/JAD-190744_ref175","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4103\/1673-5374.235240","article-title":"Gamma-aminobutyric acid A receptors in Alzheimer\u2019s disease: Highly localized remodeling of a complex and diverse signaling pathway","volume":"13","author":"Kwakowsky","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.3233\/JAD-190744_ref176","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimer\u2019s disease: A 3-month, randomized, placebo-controlled, double-blind study","volume":"8","author":"Vellas","year":"2011","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190744_ref177","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of glutamate and NMDA receptors in Alzheimer\u2019s disease","volume":"57","author":"Wang","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref178","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fphys.2012.00464","article-title":"Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer\u2019s disease","volume":"3","author":"Dinamarca","year":"2012","journal-title":"Front Physiol"},{"key":"10.3233\/JAD-190744_ref179","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1503\/jpn.110190","article-title":"Glutamate system, amyloid \u03b2 peptides and tau protein: Functional interrelationshis and relevance to Alzheimer disease pathology","volume":"38","author":"Revett","year":"2013","journal-title":"J Psychiatry Neurosci"},{"key":"10.3233\/JAD-190744_ref180","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.neuropharm.2009.01.012","article-title":"Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1\/GluN2A) receptors","volume":"56","author":"Gilling","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-190744_ref181","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ceca.2009.12.010","article-title":"Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors","volume":"47","author":"Alberdi","year":"2010","journal-title":"Cell Calcium"},{"key":"10.3233\/JAD-190744_ref182","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/aps.2009.24","article-title":"Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases","volume":"30","author":"Dong","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.3233\/JAD-190744_ref183","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12035-008-8036-x","article-title":"Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration","volume":"38","author":"Vosler","year":"2008","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-190744_ref184","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","article-title":"Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2013too little activation is bad, too much is even worse","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-190744_ref185","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneurol.2011.69","article-title":"Lack of evidence for the efficacy of memantine in mild Alzheimer disease","volume":"68","author":"Schneider","year":"2011","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-190744_ref186","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3233\/JAD-2012-121447","article-title":"Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer\u2019s disease brain","volume":"33","author":"Ni","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref187","doi-asserted-by":"crossref","first-page":"3204519","DOI":"10.1155\/2016\/3204519","article-title":"Amyloid-beta-induced dysregulation of AMPA receptor trafficking","volume":"2016","author":"Guntupalli","year":"2016","journal-title":"Neural Plast"},{"key":"10.3233\/JAD-190744_ref188","doi-asserted-by":"crossref","first-page":"14968","DOI":"10.1073\/pnas.1107411108","article-title":"Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans","volume":"108","author":"Cirrito","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190744_ref189","first-page":"236re234","article-title":"An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice","volume":"6","author":"Sheline","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-190744_ref190","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","article-title":"Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer\u2019s disease","volume":"43","author":"Garcia-Alloza","year":"2005","journal-title":"Neuropsychologia"},{"key":"10.3233\/JAD-190744_ref191","doi-asserted-by":"crossref","first-page":"13805","DOI":"10.1523\/JNEUROSCI.4218-08.2008","article-title":"Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer\u2019s disease","volume":"28","author":"Liu","year":"2008","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref192","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.trci.2018.04.005","article-title":"Established amyloid-beta pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine","volume":"4","author":"Severino","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-190744_ref193","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/cn300095t","article-title":"5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10","volume":"4","author":"Cochet","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JAD-190744_ref194","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nurt.2008.05.008","article-title":"5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer\u2019s disease","volume":"5","author":"Upton","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-190744_ref195","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: Three randomized clinical trials","volume":"319","author":"Atri","year":"2018","journal-title":"JAMA"},{"key":"10.3233\/JAD-190744_ref196","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00213-018-4862-3","article-title":"The effect of chronic stimulation of serotonin receptor type 7 on recognition, passive avoidance memory, hippocampal long-term potentiation, and neuronal apoptosis in the amyloid beta protein treated rat","volume":"235","author":"Shahidi","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.3233\/JAD-190744_ref197","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.drudis.2009.02.011","article-title":"The histamine H3 receptor as a therapeutic drug target for CNS disorders","volume":"14","author":"Gemkow","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.3233\/JAD-190744_ref198","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.tips.2011.01.003","article-title":"Histamine receptors in the CNS as targets for therapeutic intervention","volume":"32","author":"Passani","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.3233\/JAD-190744_ref199","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1358\/dnp.2010.23.2.1475899","article-title":"Therapeutic potential of histamine H3 receptor antagonists in dementias","volume":"23","author":"Chazot","year":"2010","journal-title":"Drug News Perspect"},{"key":"10.3233\/JAD-190744_ref200","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1124\/jpet.110.166876","article-title":"Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer\u2019s disease","volume":"336","author":"Brioni","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-190744_ref201","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1567205010666131212110148","article-title":"A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer\u2019s disease","volume":"11","author":"Grove","year":"2014","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190744_ref202","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2174\/1567205011310030003","article-title":"The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H(3) receptor antagonist in patients with mild to moderate Alzheimer\u2019s disease: A preliminary investigation","volume":"10","author":"Nathan","year":"2013","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190744_ref203","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3233\/JAD-161118","article-title":"Therapeutics of neurotransmitters in Alzheimer\u2019s disease","volume":"57","author":"Kandimalla","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref204","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"10.3233\/JAD-190744_ref205","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12035-014-8994-0","article-title":"The binding receptors of abeta: An alternative therapeutic target for Alzheimer\u2019s disease","volume":"53","author":"Xia","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-190744_ref206","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/exnr.2002.8018","article-title":"Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients","volume":"178","author":"Hu","year":"2002","journal-title":"Exp Neurol"},{"key":"10.3233\/JAD-190744_ref207","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1074\/jbc.M110929200","article-title":"Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling","volume":"277","author":"Yaar","year":"2002","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref208","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jnr.10703","article-title":"Characterization of the toxic mechanism triggered by Alzheimer\u2019s amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells","volume":"73","author":"Tsukamoto","year":"2003","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-190744_ref209","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1385\/JMN:25:2:141","article-title":"Characterization of the signaling pathway downstream p75 neurotrophin receptor involved in beta-amyloid peptide-dependent cell death","volume":"25","author":"Costantini","year":"2005","journal-title":"J Mol Neurosci"},{"key":"10.3233\/JAD-190744_ref210","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20011797","article-title":"Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines","volume":"195","author":"Perini","year":"2002","journal-title":"J Exp Med"},{"key":"10.3233\/JAD-190744_ref211","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1523\/JNEUROSCI.1204-14.2014","article-title":"Abeta selectively impairs mGluR7 modulation of NMDA signaling in basal forebrain cholinergic neurons: Implication in Alzheimer\u2019s disease","volume":"34","author":"Gu","year":"2014","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref212","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-140036","article-title":"Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AbetaPP(L\/S) transgenic mice","volume":"42","author":"Nguyen","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref213","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1101\/lm.030411.113","article-title":"Activation of beta2-adrenoceptor enhances synaptic potentiation and behavioral memory via cAMP-PKA signaling in the medial prefrontal cortex of rats","volume":"20","author":"Zhou","year":"2013","journal-title":"Learn Mem"},{"key":"10.3233\/JAD-190744_ref214","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1046\/j.1460-9568.2003.02620.x","article-title":"Deficit in long-term contextual fear memory induced by blockade of beta-adrenoceptors in hippocampal CA1 region","volume":"17","author":"Ji","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JAD-190744_ref215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1755-5949.2012.00341.x","article-title":"PPARgamma agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus","volume":"18","author":"Jiang","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"10.3233\/JAD-190744_ref216","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1038\/cddis.2012.189","article-title":"Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice","volume":"3","author":"Masciopinto","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.3233\/JAD-190744_ref217","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4065\/78.9.1088","article-title":"Thiazolidinedione-associated congestive heart failure and pulmonary edema","volume":"78","author":"Kermani","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.3233\/JAD-190744_ref218","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cmet.2016.07.016","article-title":"Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils","volume":"24","author":"Kirchgessner","year":"2016","journal-title":"Cell Metab"},{"key":"10.3233\/JAD-190744_ref219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.07.010","article-title":"The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease","volume":"181","author":"Fessler","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.3233\/JAD-190744_ref220","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fncel.2015.00064","article-title":"SIRT1 in the brain-connections with aging-associated disorders and lifespan","volume":"9","author":"Ng","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JAD-190744_ref221","doi-asserted-by":"crossref","first-page":"42444","DOI":"10.1074\/jbc.R112.402768","article-title":"From sirtuin biology to human diseases: An update","volume":"287","author":"Sebastian","year":"2012","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref222","doi-asserted-by":"crossref","first-page":"9695","DOI":"10.1523\/JNEUROSCI.0027-10.2010","article-title":"SIRT1 is essential for normal cognitive function and synaptic plasticity","volume":"30","author":"Michan","year":"2010","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref223","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.bbapap.2009.11.015","article-title":"The role of Sirt1: At the crossroad between promotion of longevity and protection against Alzheimer\u2019s disease neuropathology","volume":"1804","author":"Wang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-190744_ref224","doi-asserted-by":"crossref","first-page":"21745","DOI":"10.1074\/jbc.M602909200","article-title":"Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction","volume":"281","author":"Qin","year":"2006","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref225","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jnr.23310","article-title":"Attenuation of beta-amyloid-induced tauopathy via activation of CK2alpha\/SIRT1: Targeting for cilostazol","volume":"92","author":"Lee","year":"2014","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-190744_ref226","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1515\/revneuro-2016-0023","article-title":"SIRT1 as a therapeutic target for Alzheimer\u2019s disease","volume":"27","author":"Wong","year":"2016","journal-title":"Rev Neurosci"},{"key":"10.3233\/JAD-190744_ref227","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00109-012-0954-4","article-title":"12\/15-lipoxygenase during the regulation of inflammation, immunity, and self-tolerance","volume":"90","author":"Uderhardt","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"10.3233\/JAD-190744_ref228","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2016.05.023","article-title":"12\/15-lipoxygenase inhibition reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice","volume":"81","author":"Di Meco","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.3233\/JAD-190744_ref229","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.3233\/JAD-190744_ref230","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.3233\/JAD-190744_ref231","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.3233\/JAD-190744_ref232","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/iub.1104","article-title":"Phosphodiesterases in neurodegenerative disorders","volume":"64","author":"Bollen","year":"2012","journal-title":"IUBMB Life"},{"key":"10.3233\/JAD-190744_ref233","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.3233\/JAD-190744_ref234","doi-asserted-by":"crossref","first-page":"20747","DOI":"10.1016\/S0021-9258(19)36846-2","article-title":"Molecular cloning and functional expression of human acyl-coenzyme A: Cholesterol acyltransferase cDNA in mutant chinese hamster ovary cells","volume":"268","author":"Chang","year":"1993","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref235","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1074\/jbc.M111.274142","article-title":"Comparative lipidomic analysis of mouse and human brain with Alzheimer disease","volume":"287","author":"Chan","year":"2012","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref236","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JAD-2006-9202","article-title":"The key role of mitochondria in Alzheimer\u2019s disease","volume":"9","author":"Moreira","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref237","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1089\/ars.2007.1703","article-title":"Alzheimer\u2019s disease: A lesson from mitochondrial dysfunction","volume":"9","author":"Moreira","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"10.3233\/JAD-190744_ref238","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.brainresrev.2005.03.004","article-title":"Are mitochondria critical in the pathogenesis of Alzheimer\u2019s disease?","volume":"49","author":"Reddy","year":"2005","journal-title":"Brain Res Rev"},{"key":"10.3233\/JAD-190744_ref239","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/39522","article-title":"An intracellular protein that binds amyloid-\u03b2 peptide and mediates neurotoxicity in Alzheimer\u2019s disease","volume":"389","author":"Yan","year":"1997","journal-title":"Nature"},{"key":"10.3233\/JAD-190744_ref240","first-page":"100","article-title":"Amyloid beta-peptide binding alcohol dehydrogenase is a component of the cellular response to nutritional stress","volume":"275","author":"Yan","year":"2000","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref241","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jmb.2004.07.071","article-title":"Crystal structure of human ABAD\/HSD10 with a bound inhibitor: Implications for design of Alzheimer\u2019s disease therapeutics","volume":"342","author":"Kissinger","year":"2004","journal-title":"J Mol Biol"},{"key":"10.3233\/JAD-190744_ref242","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.1091230","article-title":"ABAD directly links A\u03b2 to mitochondrial toxicity in Alzheimer\u2019s disease","volume":"304","author":"Lustbader","year":"2004","journal-title":"Science"},{"key":"10.3233\/JAD-190744_ref243","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.yfrne.2007.12.005","article-title":"Estradiol and neurodegenerative oxidative stress","volume":"29","author":"Nilsen","year":"2008","journal-title":"Front Neuroendocrinol"},{"key":"10.3233\/JAD-190744_ref244","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12035-012-8281-x","article-title":"Alzheimer\u2019s disease, oestrogen and mitochondria: An ambiguous relationship","volume":"46","author":"Grimm","year":"2012","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-190744_ref245","doi-asserted-by":"crossref","first-page":"e28887","DOI":"10.1371\/journal.pone.0028887","article-title":"Inhibition of the mitochondrial enzyme ABAD restores the amyloid-\u03b2-mediated deregulation of estradiol","volume":"6","author":"Lim","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JAD-190744_ref246","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1196\/annals.1347.016","article-title":"Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer\u2019s disease","volume":"1052","author":"Alvarez-de-la-Rosa","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-190744_ref247","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.neuroscience.2004.12.029","article-title":"Glycogen synthase kinase 3\u03b2 links neuroprotection by 17\u03b2-estradiol to key Alzheimer processes","volume":"132","author":"Goodenough","year":"2005","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-190744_ref248","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.yfrne.2009.04.015","article-title":"Protective actions of sex steroid hormones in Alzheimer\u2019s disease","volume":"30","author":"Pike","year":"2009","journal-title":"Front Neuroendocrinol"},{"key":"10.3233\/JAD-190744_ref249","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1196\/annals.1386.036","article-title":"Estrogen, \u03b2-amyloid metabolism\/trafficking, and Alzheimer\u2019s disease","volume":"1089","author":"Xu","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-190744_ref250","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.neuroscience.2010.05.031","article-title":"Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer\u2019s disease","volume":"169","author":"Amtul","year":"2010","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-190744_ref251","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1096\/fj.04-2582fje","article-title":"ABAD enhances A\u03b2-induced cell stress via mitochondrial dysfunction","volume":"19","author":"Takuma","year":"2005","journal-title":"FASEB J"},{"key":"10.3233\/JAD-190744_ref252","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neuron.2007.05.033","article-title":"Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson\u2019s disease","volume":"55","author":"Qu","year":"2007","journal-title":"Neuron"},{"key":"10.3233\/JAD-190744_ref253","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S1357-2725(02)00063-8","article-title":"Endophilin-1: A multifunctional protein","volume":"34","author":"Reutens","year":"2002","journal-title":"Int J Biochem Cell Biol"},{"key":"10.3233\/JAD-190744_ref254","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1074\/jbc.M707932200","article-title":"Endophilin I expression is increased in the brains of Alzheimer disease patients","volume":"283","author":"Ren","year":"2008","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref255","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuron.2011.02.002","article-title":"Interplay between VGLUT isoforms and endophilin A1 regulates neurotransmitter release and short-term plasticity","volume":"69","author":"Weston","year":"2011","journal-title":"Neuron"},{"key":"10.3233\/JAD-190744_ref256","doi-asserted-by":"crossref","first-page":"28913","DOI":"10.1074\/jbc.M103198200","article-title":"Endophilin regulates JNK activation through its interaction with the germinal center kinase-like kinase","volume":"276","author":"Ramjaun","year":"2001","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref257","first-page":"321","article-title":"c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer\u2019s disease","volume":"6","author":"Yarza","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.3233\/JAD-190744_ref258","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1021\/acs.jmedchem.8b01530","article-title":"Amyloid-binding alcohol dehydrogenase (ABAD) inhibitors for the treatment of Alzheimer\u2019s disease","volume":"62","author":"Morsy","year":"2019","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-190744_ref259","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-2005-7203","article-title":"Differential loss of synaptic proteins in Alzheimer\u2019s disease: Implications for synaptic dysfunction","volume":"7","author":"Reddy","year":"2005","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref260","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1089\/ars.2011.4277","article-title":"Synaptic mitochondrial pathology in Alzheimer\u2019s disease","volume":"16","author":"Du","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"10.3233\/JAD-190744_ref261","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.bbamem.2011.10.001","article-title":"Glial connexin expression and function in the context of Alzheimer\u2019s disease","volume":"1818","author":"Koulakoff","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-190744_ref262","first-page":"4958","article-title":"Astroglial connexins as a therapeutic target for Alzheimer\u2019s disease","volume":"23","author":"Yi","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.3233\/JAD-190744_ref263","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fncel.2018.00432","article-title":"Astrocytes\u2019 contribution to adult neurogenesis in physiology and Alzheimer\u2019s disease","volume":"12","author":"Casse","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JAD-190744_ref264","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s12035-014-8970-8","article-title":"ATF4: A novel potential therapeutic target for Alzheimer\u2019s disease","volume":"52","author":"Wei","year":"2015","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-190744_ref265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/alzrt260","article-title":"PERK: A novel therapeutic target for neurodegenerative diseases?","volume":"6","author":"Ma","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-190744_ref266","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12640-017-9716-y","article-title":"TREM1: A potential therapeutic target for Alzheimer\u2019s disease","volume":"32","author":"Saadipour","year":"2017","journal-title":"Neurotox Res"},{"key":"10.3233\/JAD-190744_ref267","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuropharm.2016.08.022","article-title":"Ca(2+)-permeable AMPA receptor: A new perspective on amyloid-beta mediated pathophysiology of Alzheimer\u2019s disease","volume":"112","author":"Whitehead","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-190744_ref268","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/cns.12696","article-title":"Calcitonin gene-related peptide (CGRP): A novel target for Alzheimer\u2019s disease","volume":"23","author":"Singh","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"10.3233\/JAD-190744_ref269","doi-asserted-by":"crossref","first-page":"14741","DOI":"10.1523\/JNEUROSCI.3728-09.2009","article-title":"Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway","volume":"29","author":"Canas","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref270","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nbd.2018.05.024","article-title":"Blockade of adenosine A2A receptors recovers early deficits of memory and plasticity in the triple transgenic mouse model of Alzheimer\u2019s disease","volume":"117","author":"Silva","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-190744_ref271","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.expneurol.2007.11.013","article-title":"Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801","volume":"210","author":"Cunha","year":"2008","journal-title":"Exp Neurol"},{"key":"10.3233\/JAD-190744_ref272","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1248\/bpb.b16-01006","article-title":"DJ-1\/PARK7: A new therapeutic target for neurodegenerative disorders","volume":"40","author":"Hijioka","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.3233\/JAD-190744_ref273","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1152\/jn.01138.2002","article-title":"Human amylin actions on rat cholinergic basal forebrain neurons: Antagonism of beta-amyloid effects","volume":"89","author":"Jhamandas","year":"2003","journal-title":"J Neurophysiol"},{"key":"10.3233\/JAD-190744_ref274","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajpath.2010.11.022","article-title":"Actions of beta-amyloid protein on human neurons are expressed through the amylin receptor","volume":"178","author":"Jhamandas","year":"2011","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-190744_ref275","doi-asserted-by":"crossref","first-page":"17401","DOI":"10.1523\/JNEUROSCI.3028-12.2012","article-title":"Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor","volume":"32","author":"Kimura","year":"2012","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref276","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10495-011-0656-3","article-title":"Beta-amyloid protein (Abeta) and human amylin regulation of apoptotic genes occurs through the amylin receptor","volume":"17","author":"Jhamandas","year":"2012","journal-title":"Apoptosis"},{"key":"10.3233\/JAD-190744_ref277","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2014.17","article-title":"Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer\u2019s disease","volume":"20","author":"Zhu","year":"2015","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-190744_ref278","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3233\/JAD-160800","article-title":"Amylin enhances amyloid-beta peptide brain to blood efflux across the blood-brain barrier","volume":"56","author":"Mohamed","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref279","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.trci.2016.11.005","article-title":"Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer\u2019s disease","volume":"3","author":"Soudy","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-190744_ref280","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI119772","article-title":"Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer\u2019s disease","volume":"100","author":"Yaar","year":"1997","journal-title":"J Clin Invest"},{"key":"10.3233\/JAD-190744_ref281","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1523\/JNEUROSCI.0350-08.2008","article-title":"Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor","volume":"28","author":"Sotthibundhu","year":"2008","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref282","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/187152708783885093","article-title":"Small molecule modulation of p75 neurotrophin receptor functions","volume":"7","author":"Longo","year":"2008","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.3233\/JAD-190744_ref283","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1523\/JNEUROSCI.0620-09.2009","article-title":"The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo","volume":"29","author":"Knowles","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref284","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.neurobiolaging.2013.02.015","article-title":"Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer\u2019s mouse model","volume":"34","author":"Knowles","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190744_ref285","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/jnc.14206","article-title":"p75 neurotrophin receptor interacts with and promotes BACE1 localization in endosomes aggravating amyloidogenesis","volume":"144","author":"Saadipour","year":"2018","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-190744_ref286","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1096\/fj.10-156661","article-title":"Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity","volume":"24","author":"Wang","year":"2010","journal-title":"FASEB J"},{"key":"10.3233\/JAD-190744_ref287","doi-asserted-by":"crossref","first-page":"10298","DOI":"10.1074\/jbc.M112.415141","article-title":"Beta2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models","volume":"288","author":"Wang","year":"2013","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref288","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.neuron.2012.12.040","article-title":"Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers","volume":"77","author":"Li","year":"2013","journal-title":"Neuron"},{"key":"10.3233\/JAD-190744_ref289","doi-asserted-by":"crossref","first-page":"31852","DOI":"10.1074\/jbc.M111.244335","article-title":"Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons","volume":"286","author":"Wang","year":"2011","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref290","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/nm1485","article-title":"Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation","volume":"12","author":"Ni","year":"2006","journal-title":"Nat Med"},{"key":"10.3233\/JAD-190744_ref291","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.neurobiolaging.2007.12.004","article-title":"Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP\/PKA signalling pathway","volume":"30","author":"Wang","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190744_ref292","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2016.11.022","article-title":"Activation of beta2-adrenergic receptor promotes dendrite ramification and spine generation in APP\/PS1 mice","volume":"636","author":"Chai","year":"2017","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-190744_ref293","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4103\/1673-5374.193241","article-title":"Beta 2-adrenergic receptor activation enhances neurogenesis in Alzheimer\u2019s disease mice","volume":"11","author":"Chai","year":"2016","journal-title":"Neural Regen Res"},{"key":"10.3233\/JAD-190744_ref294","doi-asserted-by":"crossref","first-page":"e0196943","DOI":"10.1371\/journal.pone.0196943","article-title":"Probing the role of PPARgamma in the regulation of late-onset Alzheimer\u2019s disease-associated genes","volume":"13","author":"Barrera","year":"2018","journal-title":"PLoS One"},{"key":"10.3233\/JAD-190744_ref295","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.expneurol.2006.01.018","article-title":"Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice","volume":"199","author":"Pedersen","year":"2006","journal-title":"Exp Neurol"},{"key":"10.3233\/JAD-190744_ref296","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40266-014-0228-7","article-title":"Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer\u2019s disease and amnestic mild cognitive impairment: A systematic review and meta-analysis","volume":"32","author":"Liu","year":"2015","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-190744_ref297","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/npp.2010.32","article-title":"Rosiglitazone rescues memory impairment in Alzheimer\u2019s transgenic mice: Mechanisms involving a reduced amyloid and tau pathology","volume":"35","author":"Escribano","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.3233\/JAD-190744_ref298","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1210\/mend.16.6.0835","article-title":"Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system","volume":"16","author":"Whitney","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.3233\/JAD-190744_ref299","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.2011.594043","article-title":"Nuclear receptors as therapeutic targets for Alzheimer\u2019s disease","volume":"15","author":"Mandrekar-Colucci","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.3233\/JAD-190744_ref300","doi-asserted-by":"crossref","first-page":"43243","DOI":"10.1074\/jbc.M508781200","article-title":"The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease","volume":"280","author":"Hirsch-Reinshagen","year":"2005","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-190744_ref301","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3233\/JAD-2011-110854","article-title":"Processing of endogenous AbetaPP in blood-brain barrier endothelial cells is modulated by liver-X receptor agonists and altered cellular cholesterol homeostasis","volume":"27","author":"Schweinzer","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190744_ref302","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s11064-011-0513-3","article-title":"Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels","volume":"36","author":"Cui","year":"2011","journal-title":"Neurochem Res"},{"key":"10.3233\/JAD-190744_ref303","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuroscience.2017.07.053","article-title":"Amelioration of amyloid beta-induced retinal inflammatory responses by a LXR agonist TO901317 is associated with inhibition of the NF-kappaB signaling and NLRP3 inflammasome","volume":"360","author":"Lei","year":"2017","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-190744_ref304","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.pathol.4.110807.092250","article-title":"Mammalian sirtuins: Biological insights and disease relevance","volume":"5","author":"Haigis","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"10.3233\/JAD-190744_ref305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbrc.2014.04.066","article-title":"Activation of SIRT1 by curcumin blocks the neurotoxicity of amyloid-beta25-35 in rat cortical neurons","volume":"448","author":"Sun","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-190744_ref306","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12017-014-8288-8","article-title":"Distinct patterns of sirtuin expression during progression of Alzheimer\u2019s disease","volume":"16","author":"Lutz","year":"2014","journal-title":"Neuromolecular Med"},{"key":"10.3233\/JAD-190744_ref307","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.bbadis.2014.05.015","article-title":"Leptin attenuates BACE1 expression and amyloid-beta genesis via the activation of SIRT1 signaling pathway","volume":"1842","author":"Marwarha","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-190744_ref308","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tem.2013.12.001","article-title":"SIRT1 and other sirtuins in metabolism","volume":"25","author":"Chang","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"10.3233\/JAD-190744_ref309","doi-asserted-by":"crossref","first-page":"e59888","DOI":"10.1371\/journal.pone.0059888","article-title":"Resveratrol inhibits beta-amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-190744_ref310","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1038\/sj.emboj.7601758","article-title":"SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer\u2019s disease and amyotrophic lateral sclerosis","volume":"26","author":"Kim","year":"2007","journal-title":"EMBO J"},{"key":"10.3233\/JAD-190744_ref311","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.biopsych.2010.04.010","article-title":"Amelioration of the Alzheimer\u2019s disease phenotype by absence of 12\/15-lipoxygenase","volume":"68","author":"Yang","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.3233\/JAD-190744_ref312","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.neurobiolaging.2012.12.009","article-title":"5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: Involvement of the cyclin-dependent kinase-5","volume":"34","author":"Chu","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190744_ref313","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.biopsych.2015.01.015","article-title":"Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy","volume":"78","author":"Giannopoulos","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.3233\/JAD-190744_ref314","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2012.06.048","article-title":"Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe\/PS1dE9 mouse model of Alzheimer\u2019s disease","volume":"64","author":"Sierksma","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-190744_ref315","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuropharm.2012.06.052","article-title":"Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD","volume":"64","author":"Garcia-Barroso","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-190744_ref316","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2018.06.002","article-title":"Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer\u2019s disease","volume":"138","author":"Gulisano","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-190744_ref317","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/1567205011666140505100858","article-title":"A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer\u2019s disease","volume":"11","author":"Schwam","year":"2014","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190744_ref318","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbr.2013.05.017","article-title":"Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP\/PS1 transgenic mice","volume":"250","author":"Zhang","year":"2013","journal-title":"Behav Brain Res"},{"key":"10.3233\/JAD-190744_ref319","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrn3012","article-title":"Linking lipids to Alzheimer\u2019s disease: Cholesterol and beyond","volume":"12","author":"Di Paolo","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-190744_ref320","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1471-4159.2007.04715.x","article-title":"Alzheimer\u2019s disease: The lipid connection","volume":"103 Suppl 1","author":"Hartmann","year":"2007","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-190744_ref321","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1073\/pnas.0913828107","article-title":"ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD","volume":"107","author":"Bryleva","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190744_ref322","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/NEN.0b013e3181e77ed9","article-title":"The acyl-coenzyme A: Cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice","volume":"69","author":"Huttunen","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-190744_ref323","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/mt.2013.118","article-title":"Acat1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer\u2019s disease","volume":"21","author":"Murphy","year":"2013","journal-title":"Mol Ther"},{"key":"10.3233\/JAD-190744_ref324","doi-asserted-by":"crossref","first-page":"14484","DOI":"10.1523\/JNEUROSCI.2567-14.2014","article-title":"Inhibiting ACAT1\/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Abeta1-42 clearance","volume":"34","author":"Shibuya","year":"2014","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref325","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.neurobiolaging.2015.04.002","article-title":"Acyl-coenzyme A: Cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer\u2019s disease mouse and reduces human P301L-tau content at the presymptomatic stage","volume":"36","author":"Shibuya","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190744_ref326","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-190744_ref327","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fneur.2014.00182","article-title":"Current animal models of Alzheimer\u2019s disease: Challenges in translational research","volume":"5","author":"Cuadrado-Tejedor","year":"2014","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-190744_ref328","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-4933-9-3","article-title":"Simple model systems: A challenge for Alzheimer\u2019s disease","volume":"9","author":"Di Carlo","year":"2012","journal-title":"Immun Ageing"},{"key":"10.3233\/JAD-190744_ref329","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13195-017-0268-4","article-title":"Stem cell models of Alzheimer\u2019s disease: Progress and challenges","volume":"9","author":"Arber","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-190744_ref330","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41593-018-0175-4","article-title":"A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer\u2019s disease","volume":"21","author":"Park","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-190744_ref331","first-page":"135","article-title":"Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer\u2019s disease","volume":"2","author":"Morris","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-190744_ref332","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neurobiolaging.2006.10.027","article-title":"Alzheimer\u2019s presenilin 1 causes chromosome missegregation and aneuploidy","volume":"29","author":"Boeras","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190744_ref333","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1523\/JNEUROSCI.5901-11.2012","article-title":"Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-beta1-42 oligomers are revealed in vivo by using a novel animal model","volume":"32","author":"Brouillette","year":"2012","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-190744_ref334","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1590\/S1980-57642009DN30300003","article-title":"Neurobiological pathways to Alzheimer\u2019s disease: Amyloid-beta, tau protein or both?","volume":"3","author":"de Paula","year":"2009","journal-title":"Dement Neuropsychol"},{"key":"10.3233\/JAD-190744_ref335","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1742-2094-1-23","article-title":"Beta-Amyloid promotes accumulation of lipid peroxides by inhibiting CD36-mediated clearance of oxidized lipoproteins","volume":"1","author":"Kunjathoor","year":"2004","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-190744_ref336","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.npep.2009.10.006","article-title":"Participation of kinin receptors on memory impairment after chronic infusion of human amyloid-beta 1-40 peptide in mice","volume":"44","author":"Amaral","year":"2010","journal-title":"Neuropeptides"},{"key":"10.3233\/JAD-190744_ref337","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.neuroscience.2008.04.036","article-title":"Minocycline provides protection against beta-amyloid(25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex","volume":"154","author":"Burgos-Ramos","year":"2008","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-190744_ref338","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbr.2011.08.024","article-title":"Behavioural and cellular effects of exogenous amyloid-beta peptides in rodents","volume":"225","author":"Chambon","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.3233\/JAD-190744_ref339","doi-asserted-by":"crossref","first-page":"8852","DOI":"10.1073\/pnas.0602896103","article-title":"Beta-amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits","volume":"103","author":"Malm","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190744_ref340","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.nlm.2007.03.010","article-title":"Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice","volume":"88","author":"Dineley","year":"2007","journal-title":"Neurobiol Learn Mem"},{"key":"10.3233\/JAD-190744_ref341","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.neurobiolaging.2003.11.007","article-title":"Impaired conditioned taste aversion learning in APP transgenic mice","volume":"25","author":"Janus","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190744_ref342","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13024-016-0139-7","article-title":"3D culture models of Alzheimer\u2019s disease: A road map to a \u201ccure-in-a-dish\u201d","volume":"11","author":"Choi","year":"2016","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-190744_ref343","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-190744_ref344","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-190744_ref345","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/JIR.S86958","article-title":"Targeting neuroinflammation in Alzheimer\u2019s disease","volume":"9","author":"Bronzuoli","year":"2016","journal-title":"J\u00a0Inflamm Res"},{"key":"10.3233\/JAD-190744_ref346","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-161141","article-title":"The gut microbiota and Alzheimer\u2019s disease","volume":"58","author":"Jiang","year":"2017","journal-title":"J Alzheimers Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-190744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:10Z","timestamp":1777370830000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-190744"}},"subtitle":[],"editor":[{"given":"P. Hemachandra","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":346,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-190744","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,27]]}}}